REG - Diaceutics PLC - Transaction by Persons Closely Associated to PDMRs

DiaceuticsAnnouncement

15/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250515:nRSO7261Ia&default-theme=true

RNS Number : 7261I  Diaceutics PLC  15 May 2025

 Notification of Transaction by Persons Closely Associated ("PCAs") to
Persons Discharging Managerial Responsibilities ("PDMRs")

 

New York, Belfast and London, 15 May 2025 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, announces that it has been
notified that on 13 May 2025, Delia Keeling, a person closely associated with
Peter Keeling, Chair of Diaceutics, and  spouse of Peter Keeling, sold
500,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares")
at a price of 126 pence per Ordinary Share. As a result of the sale, Peter
and Delia Keeling's combined shareholding in Diaceutics is 15,252,049 Ordinary
Shares representing approximately 17.98% of the Company's issued share
capital.

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of
the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in
accordance with the Company's obligations under Article 17 of MAR. The person
responsible for making this announcement on behalf of the Company is Nick
Roberts, Chief Financial Officer.

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Delia Keeling
 2   Reason for notification
 a.  Position/Status                                              PCA to Peter Keeling, Chair
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics PLC
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.002 each

Identification Code

                                                                  ISIN:  GB00BJQTGV64
 b.  Nature of the transaction                                    Sale
 c.  Price(s) and volume(s)
                                                                               Price(s)     Volume(s)
     £1.26                                                                     500,000

 d.  Date of the transaction                                      13 May 2025
 e.  Place of the transaction                                     AIM Market of the London Stock Exchange

 

TR-1: Standard form for notification of major holdings

 NOTIFICATION OF MAJOR HOLDINGS
 1a. Identity of the issuer or the underlying issuer of existing shares to                                                                                    Diaceutics PLC ORD GBP0.002
 which voting rights are attached (ii):
 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an
 "X" if appropriate)
 Non-UK issuer
 2. Reason for the notification (please mark the appropriate box or boxes with
 an "X")
 An acquisition or disposal of voting rights                                                                                                                                                                                                               X
 An acquisition or disposal of financial instruments
 An event changing the breakdown of voting rights
 Other (please specify) (iii):
 3. Details of person subject to the notification obligation (iv)
 Name                                                                                                                                                         Peter & Delia Keeling
 City and country of registered office (if applicable)                                                                                                        NA
 4. Full name of shareholder(s) (if different from 3.) (v)
 Name
 City and country of registered office (if applicable)
 5. Date on which the threshold was crossed or reached (vi):                                                                                                  13 May, 2025
 6. Date on which issuer notified:                                                                                                                            13 May, 2025
 7. Total positions of person(s) subject to the notification obligation
                                                                            % of voting rights attached to shares (total of 8. A)  % of voting rights through financial instruments      Total of both in % (8.A + 8.B)  Total number of voting rights held in issuer (8.A + 8.B) (vii)

(total of 8.B 1 + 8.B 2)
 Resulting situation on the date on which threshold was crossed or reached  17.98%                                                                                                       17.98%
 Position of previous notification (if applicable)                          18.60%                                                                                                       18.60%

 

 8. Notified details of the resulting situation on the date on which the
 threshold was crossed or reached (viii)
 A: Voting rights attached to shares
 Class/type of                                  Number of voting rights (ix)                                                 % of voting rights

shares

 ISIN code (if possible)
                                                Direct                     Indirect                                          Direct                                           Indirect

                                                (DTR5.1)                    (DTR5.2.1)                                       (DTR5.1)                                         (DTR5.2.1)
 GB00BJQTGV64                                   15,252,049                                                                   17.98%

 SUBTOTAL 8. A                                  15,252,049

 B 1: Financial Instruments according to DTR5.3.1R (1) (a)
 Type of financial instrument                   Expiration  Exercise/                                Number of voting rights that may be acquired if the instrument is        % of voting rights

date (x)
Conversion Period (xi)

                                                                                                     exercised/converted.

                                                            SUBTOTAL 8. B 1

 B 2: Financial Instruments with similar economic effect according to DTR5.3.1R
 (1) (b)
 Type of financial instrument  Expiration                   Exercise/                     Physical or cash                                           Number of voting rights  % of voting rights

date (x)
Conversion Period (xi)

                                                                                          Settlement (xii)

                                                                                          SUBTOTAL 8.B.2

 

 9. Information in relation to the person subject to the notification
 obligation (please mark the applicable box with an "X")
 Person subject to the notification obligation is not controlled by any natural
 person or legal entity and does not control any other undertaking(s) holding
 directly or indirectly an interest in the (underlying) issuer (xiii)
 Full chain of controlled undertakings through which the voting rights and/or
 the

financial instruments are effectively held starting with the ultimate
 controlling natural person or legal entity (please add additional rows as
 necessary) (xiv)
 Name (xv)                   % of voting rights if it equals or is higher than the notifiable threshold  % of voting rights through financial instruments if it equals or is higher  Total of both if it equals or is higher than the notifiable threshold
                                                                                                         than the notifiable threshold

 10. In case of proxy voting, please identify:
 Name of the proxy holder
 The number and % of voting rights held
 The date until which the voting rights will be held

 11. Additional information (xvi)

 

 Place of completion  AIM Stock Exchange, London
 Date of completion    13 May, 2025

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFVDEEISLIE